Management of atypical uremic hemolytic syndrome in pregnant patient.

Autor: Simón Polo E; Anestesiología y Reanimación, Complejo Hospitalario Universitario de Albacete, Albacete, España. Electronic address: elsimhz@hotmail.com., Hernández Laforet J; Anestesiología y Reanimación, Hospital General Universitario de Valencia, Valencia, España., Carretero de la Encarnación B; Anestesiología y Reanimación, Complejo Hospitalario Universitario de Albacete, Albacete, España., Monsalve Naharro JA; Anestesiología y Reanimación, Complejo Hospitalario Universitario de Albacete, Albacete, España.
Jazyk: English; Spanish; Castilian
Zdroj: Revista espanola de anestesiologia y reanimacion [Rev Esp Anestesiol Reanim (Engl Ed)] 2021 May 21. Date of Electronic Publication: 2021 May 21.
DOI: 10.1016/j.redar.2020.12.012
Abstrakt: Atypical uremic haemolytic syndrome is a variant of thrombotic micro-andiopathy characterized by non-autoimmune hemolytic anemia, thrombocytopenia and acute renal failure as a result of excessive activation of the complement. Up to 60% of patients have mutations in the genes that encode the complement system. A disensing factor is required for its manifestation, including gestation. It is an entity with a high morbidity, which can decrease drastically if an early diagnosis is made and appropriate treatment is initiated. Administration of ecuilizumab has demonstrated rapid process disruption, reducing the need for extrarenal purification therapies and improving renal function and patient prognosis.
(Publicado por Elsevier España, S.L.U.)
Databáze: MEDLINE
Externí odkaz: